These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 16172229)

  • 41. Ratios of free to total prostate-specific antigen and total prostate specific antigen to protein concentrations in saliva and serum of healthy men.
    Ayatollahi H; Darabi Mahboub MR; Mohammadian N; Parizadeh MR; Kianoosh T; Khabbaz Khoob M; Kamalian F
    Urol J; 2007; 4(4):238-41. PubMed ID: 18270950
    [TBL] [Abstract][Full Text] [Related]  

  • 42. hK2 and free PSA, a prognostic combination in predicting minimal prostate cancer in screen-detected men within the PSA range 4-10 ng/ml.
    Raaijmakers R; de Vries SH; Blijenberg BG; Wildhagen MF; Postma R; Bangma CH; Darte C; Schröder FH
    Eur Urol; 2007 Nov; 52(5):1358-64. PubMed ID: 17499425
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Adding free to total prostate-specific antigen levels in trials of prostate cancer screening.
    Wald NJ; Watt HC; George L; Knekt P; Helzlsouer KJ; Tuomilehto J
    Br J Cancer; 2000 Feb; 82(3):731-6. PubMed ID: 10682690
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Evidence of prostate cancer screening in a UK region.
    Gavin A; McCarron P; Middleton RJ; Savage G; Catney D; O'Reilly D; Keane PF; Murray LJ
    BJU Int; 2004 Apr; 93(6):730-4. PubMed ID: 15049981
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Screening for prostate cancer in U.S. men ACPM position statement on preventive practice.
    Lim LS; Sherin K;
    Am J Prev Med; 2008 Feb; 34(2):164-70. PubMed ID: 18201648
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Large-scale study of clinical impact of PSA velocity: long-term PSA kinetics as method of differentiating men with from those without prostate cancer.
    Berger AP; Deibl M; Strasak A; Bektic J; Pelzer AE; Klocker H; Steiner H; Fritsche G; Bartsch G; Horninger W
    Urology; 2007 Jan; 69(1):134-8. PubMed ID: 17270635
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The influence of statin medications on prostate-specific antigen levels.
    Hamilton RJ; Goldberg KC; Platz EA; Freedland SJ
    J Natl Cancer Inst; 2008 Nov; 100(21):1511-8. PubMed ID: 18957682
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prostate specific antigen testing in men older than 75 years in the United States.
    Scales CD; Curtis LH; Norris RD; Schulman KA; Albala DM; Moul JW
    J Urol; 2006 Aug; 176(2):511-4. PubMed ID: 16813879
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Age-related free PSA, total PSA and free PSA/total PSA ratios: establishment of reference ranges in Chinese males.
    Kao CH
    Anticancer Res; 1997; 17(2B):1361-5. PubMed ID: 9137499
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Is the utility of prostate-specific antigen velocity for prostate cancer detection affected by age?
    Loeb S; Roehl KA; Catalona WJ; Nadler RB
    BJU Int; 2008 Apr; 101(7):817-21. PubMed ID: 18321315
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Age-specific reference levels of serum prostate-specific antigen and prostate volume in healthy Arab men.
    Kehinde EO; Mojiminiyi OA; Sheikh M; Al-Awadi KA; Daar AS; Al-Hunayan A; Anim JT; Al-Sumait AA
    BJU Int; 2005 Aug; 96(3):308-12. PubMed ID: 16042719
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Specificity of serum prostate-specific antigen determination in the Finnish prostate cancer screening trial.
    Määttänen L; Hakama M; Tammela TL; Ruutu M; Ala-Opas M; Juusela H; Martikainen P; Stenman UH; Auvinen A
    Br J Cancer; 2007 Jan; 96(1):56-60. PubMed ID: 17213825
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Obesity and screening PSA levels among men undergoing an annual physical exam.
    Rundle A; Neugut AI
    Prostate; 2008 Mar; 68(4):373-80. PubMed ID: 18189231
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical utility of proPSA and "benign" PSA when percent free PSA is less than 15%.
    Khan MA; Sokoll LJ; Chan DW; Mangold LA; Mohr P; Mikolajczyk SD; Linton HJ; Evans CL; Rittenhouse HG; Partin AW
    Urology; 2004 Dec; 64(6):1160-4. PubMed ID: 15596190
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Influence of age on serum prostate specific antigen concentration].
    Wang Z; Liu D; Zhau L
    Zhonghua Wai Ke Za Zhi; 1996 Jun; 34(6):368-9. PubMed ID: 9594181
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Age-specific patterns of prostate-specific antigen testing among primary care physician visits.
    McNaughton Collins M; Stafford RS; Barry MJ
    J Fam Pract; 2000 Feb; 49(2):169-72. PubMed ID: 10718695
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Age-associated increase of prostate-specific antigen in a high level of men visiting urological clinics.
    Kobayashi T; Kinoshita H; Nishizawa K; Mitsumori K; Ogawa O; Kamoto T
    Int J Urol; 2005 Aug; 12(8):733-8. PubMed ID: 16174047
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Population-based analysis of normal Total PSA and percentage of free/Total PSA values: results from screening cohort.
    Capitanio U; Perrotte P; Zini L; Suardi N; Antebi E; Cloutier V; Jeldres C; Shariat SF; Duclos A; Arjane P; Saad F; Montorsi F; Karakiewicz PI
    Urology; 2009 Jun; 73(6):1323-7. PubMed ID: 19376563
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Relationship among initial serum prostate specific antigen, prostate specific antigen progression and prostate cancer detection at repeat screening visits.
    Candas B; Labrie F; Gomez JL; Cusan L; Chevrette E; Lévesque J; Brousseau G
    J Urol; 2006 Feb; 175(2):510-6; discussion 516-7. PubMed ID: 16406983
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Trends in prostate-specific antigen testing from 1995 through 2004.
    Farwell WR; Linder JA; Jha AK
    Arch Intern Med; 2007 Dec; 167(22):2497-502. PubMed ID: 18071173
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.